StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Friday. The brokerage issued a sell rating on the stock.

CEL-SCI Price Performance

CEL-SCI stock opened at $0.42 on Friday. The company has a fifty day simple moving average of $0.55 and a 200-day simple moving average of $0.89. The company has a quick ratio of 1.09, a current ratio of 1.31 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $30.76 million, a price-to-earnings ratio of -0.81 and a beta of 0.65. CEL-SCI has a 52-week low of $0.36 and a 52-week high of $3.08.

Institutional Trading of CEL-SCI

A number of hedge funds and other institutional investors have recently modified their holdings of CVM. Renaissance Technologies LLC lifted its stake in shares of CEL-SCI by 29.9% in the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after purchasing an additional 40,000 shares during the last quarter. Calton & Associates Inc. acquired a new position in CEL-SCI in the third quarter valued at about $50,000. Geode Capital Management LLC boosted its stake in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after buying an additional 53,879 shares during the period. Finally, Plotkin Financial Advisors LLC purchased a new stake in shares of CEL-SCI in the 3rd quarter valued at approximately $98,000. 12.08% of the stock is owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.